statistiche ricercatore

Nazione	#
US - Stati Uniti d'America	1.143
CN - Cina	213
RU - Federazione Russa	213
SG - Singapore	164
GB - Regno Unito	114
DK - Danimarca	72
DE - Germania	65
IT - Italia	63
VN - Vietnam	59
SE - Svezia	48
BR - Brasile	36
FR - Francia	33
IN - India	21
FI - Finlandia	19
JP - Giappone	17
KR - Corea	15
HK - Hong Kong	14
IE - Irlanda	13
BE - Belgio	12
SN - Senegal	12
CI - Costa d'Avorio	11
CZ - Repubblica Ceca	9
PL - Polonia	8
UA - Ucraina	8
AL - Albania	7
CA - Canada	7
ES - Italia	6
LT - Lituania	6
MX - Messico	6
NL - Olanda	6
BD - Bangladesh	5
MA - Marocco	5
TR - Turchia	5
MY - Malesia	4
AR - Argentina	3
AT - Austria	3
EC - Ecuador	3
ID - Indonesia	3
TN - Tunisia	3
AU - Australia	2
CL - Cile	2
GR - Grecia	2
HR - Croazia	2
IQ - Iraq	2
KE - Kenya	2
KH - Cambogia	2
LV - Lettonia	2
PK - Pakistan	2
RO - Romania	2
RS - Serbia	2
AZ - Azerbaigian	1
BG - Bulgaria	1
CO - Colombia	1
CY - Cipro	1
ET - Etiopia	1
IR - Iran	1
KG - Kirghizistan	1
LA - Repubblica Popolare Democratica del Laos	1
MW - Malawi	1
NO - Norvegia	1
NP - Nepal	1
PA - Panama	1
PH - Filippine	1
SA - Arabia Saudita	1
TH - Thailandia	1
TW - Taiwan	1
UZ - Uzbekistan	1
VE - Venezuela	1
ZA - Sudafrica	1
Totale	2.495

Nome	#
Modulation of 17β-Estradiol Signaling on Cellular Proliferation by Caveolin-2.	316
Dynamin II is required for 17β-estradiol signaling and autophagy-based ERα degradation	306
Emetine induces estrogen receptor alpha degradation and prevents 17β-estradiol-induced breast cancer cell proliferation	297
A high throughput method to study the physiology of E2:ERα signaling in breast cancer cells.	264
A functional drug re-purposing screening identifies carfilzomib as a drug preventing 17β-estradiol: ERα signaling and cell proliferation in breast cancer cells.	236
In silico screening for ERα down modulators identifies thioridazine as an anti-proliferative agent in primary, 4OH-tamoxifen-resistant and Y537S ERα-expressing breast cancer cells.	221
Ouabain and Digoxin Activate the Proteasome and the Degradation of the ERalpha in Cells Modeling Primary and Metastatic Breast Cancer	208
Strategies to degrade estrogen receptor α in primary and ESR1 mutant-expressing metastatic breast cancer.	185
Real-time measurement of E2: ERα transcriptional activity in living cells.	174
A New Anti-Estrogen Discovery Platform Identifies FDA-Approved Imidazole Anti-Fungal Drugs as Bioactive Compounds Against ERalpha Expressing Breast Cancer Cells	172
The extra-nuclear interactome of the estrogen receptors: implications for physiological functions	162
Totale	2.541

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2020/2021	47	0	0	0	0	0	0	0	0	0	16	19	12
2021/2022	146	20	5	13	5	20	5	18	9	14	3	12	22
2022/2023	251	19	44	23	44	19	43	0	18	24	2	13	2
2023/2024	163	4	4	6	19	10	25	22	21	3	7	15	27
2024/2025	391	4	9	28	7	5	15	170	66	20	23	22	22
2025/2026	636	68	59	47	87	79	39	124	17	66	50	0	0
Totale													2.541

Benvenuti nell'Anagrafe della Ricerca d'Ateneo